Taken together, our study demonstrates that CDK4/6 inhibitors selectively suppress PTEN expressed human GBM cells through down-regulation of ERK and Akt signaling, offering a proof-of-concept that suppression two key signaling pathways is a potential strategy for GBM treatment. The gene discussed is CDK4; the disease is glioblastoma.